10098388Development of Automated and Computerized Antibody Drug Conjugate Biomanufacturing DeviceClosedCollaborative R&DInnovate UKADC is an emerging class of advanced precision biotherapeutics that utilize antibodies to target specific drug payloads to specific cells or tissues. iProgen has been involved in ADC discovery and development for the past 9 years, partnering with multiple industry and academic institutions. Initially concentrating on oncology, ADC has expanded to non-oncology uses, including vaccines and anti-bacterial therapeutics. The development and production of ADC are intricate, costly, and lengthy. Most industrial/clinical scale ADC manufacturing is conducted in China. The project is dedicated to the creation of an ADC Biomanufacturing platform (ADC Biocomputer). This platform aims to revolutionize ADC manufacturing, making it integrated, scalable, and eventually, compliant with cGMP standards. In order to accelerate and democratize ADC development there is a significant need for affordable R&D tools that allow a seamless transition to manufacturing. In particular, there is a demand for tools that can improve yields, automate robust protocols and enable predictive scaling from R&D scale to population scale. We aim to develop a customizable, streamlined and automated ADC biomanufacturing device that integrates microfluidics and AI. This innovation would simplify the ADC production process within a single apparatus, significantly accelerating production, minimizing waste, and enhancing both quality and accessibility. This is an ambitious project from two pioneering biotech companies. iProgen Biotech is a Canada based preclinical stage biotech company focused on innovating ADC therapeutics. BioLogIC Technologies is an UK based SME biotech company building the Biocomputer platform.